Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

351
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
351
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

499
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
499
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K
T Cell Types and Functions01:24

T Cell Types and Functions

1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
GPCR Desensitization01:12

GPCR Desensitization

6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dendritic Cell α-Ketoglutarate Regulates Tfh Polarization in Allergy.

Allergy·2026
Same author

Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases.

Clinical reviews in allergy & immunology·2026
Same author

Precision Medicine in Inflammatory Bowel Disease: The Emerging Role of Metabolic Dysfunction.

Journal of personalized medicine·2026
Same author

IL-17RA signaling promotes the dedifferentiation of Paneth progenitors through ADAM17 to regenerate gut epithelium post-irradiation.

Nature communications·2026
Same author

Methamphetamine-associated PAH on the rise in the US: geographic trends & disparities in patient demographics and treatment strategies.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Jul 23, 2025

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.4K

Inhibiting Isoprenylation Suppresses FcεRI-Mediated Mast Cell Function and Allergic Inflammation.

Jordan M Dailey1, Sydney A Kee2, Anuj Tharakan1

  • 1Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA.

Journal of Immunology (Baltimore, Md. : 1950)
|July 14, 2023
PubMed
Summary

Targeting protein isoprenylation, not cholesterol, effectively inhibits mast cell activation. This novel approach using FGTI-2734 shows promise for treating allergic diseases like anaphylaxis and asthma.

More Related Videos

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

10.4K
Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI
07:31

Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI

Published on: November 1, 2014

12.5K

Related Experiment Videos

Last Updated: Jul 23, 2025

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.4K
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

10.4K
Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI
07:31

Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI

Published on: November 1, 2014

12.5K

Area of Science:

  • Immunology
  • Pharmacology
  • Molecular Biology

Background:

  • Immunoglobulin E (IgE)-mediated mast cell activation drives allergic diseases.
  • Statins reduce asthma severity but their mechanism in mast cells is unclear and variable.
  • Statin effects on mast cells are linked to protein isoprenylation, not cholesterol reduction.

Purpose of the Study:

  • To investigate targeting protein isoprenylation as a novel strategy for allergic disease intervention.
  • To circumvent statin resistance by directly inhibiting isoprenylation pathways.

Main Methods:

  • Genetic depletion of isoprenylation enzymes (farnesyltransferase, geranylgeranyl transferase 1) and K-Ras.
  • Pharmacological inhibition using the dual inhibitor FGTI-2734.
  • Assessment of mast cell degranulation, cytokine production, and in vivo allergic models.

Main Results:

  • Genetic and pharmacological inhibition of isoprenylation significantly reduced FcεRI-mediated mast cell degranulation and cytokine release.
  • Inhibition of both farnesyltransferase and geranylgeranyl transferase 1 is necessary for efficacy.
  • K-Ras was identified as a critical isoprenylation target.
  • FGTI-2734 effectively suppressed in vivo mast cell-dependent anaphylaxis, allergic pulmonary inflammation, and airway hyperresponsiveness.

Conclusions:

  • Protein isoprenylation, particularly of K-Ras, is critical for FcεRI-induced mast cell function.
  • Targeting isoprenylation pathways offers a novel therapeutic strategy for allergic diseases.
  • FGTI-2734 demonstrates in vivo efficacy, suggesting its potential for clinical application in allergy treatment.